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Short title: Colchicine responsive chronic recurrent multifocal osteomyelitis with MEFV 
mutations  
Key message: The MEFV gene might be associated with more than typical FMF. 
Sir, Familial Mediterranean fever (FMF) is an autosomal recessive disease 
characterized by self-limited recurrent attacks of fever with serositis such as peritonitis, 
pleuritis and arthritis [1]. FMF is caused by mutations in MEFV gene [2]. This gene had 
been considered to be responsible only for FMF in the past, however, recent reports 
show that MEFV gene is associated with more than typical FMF and is linked to 
additional clinical presentations within the family of the autoinflammatory diseases [2-4].  
Here, we describe a case of colchicine responsive chronic recurrent multifocal 
osteomyelitis (CRMO) with MEFV gene mutations. 
  A 14-year-old female was referred with fever of unknown origin persisting for 15 days. 
Physical examination was unremarkable. Laboratory findings showed normal white 
blood cell count (3.9 ×109/L), high levels of CRP (3.1mg/dl), accelerated erythrocyte 
sedimentation rate (72mm/h), normal levels of immunoglobulins and negative 
autoantibodies.  Blood culture was negative. Unexpectedly, gallium (Ga) scintigraphy 
on day 3 after admission demonstrated significant uptake in bilateral proximal region of 
tibia (Figure A).  Plain radiography showed no significant findings (Figure D) but 
magnetic resonance imaging (MRI) demonstrated multifocal lesions whose intensity 
was low in T1 weighted condition, high in T2 weighted condition in bilateral tibia (Figure 
E).  The biopsy of left tibia showed non-specific inflammatory changes and no 
malignant cells. The culture of bone marrow was negative. She had severe pain of left 
heel on day 21. MRI on day 23 demonstrated multifocal lesions whose intensity was 
low in T1 weighted condition, high in T2 weighted condition in bilateral tarsal bones 
(Figure F). Ga scintigraphy on day 38 demonstrated significant uptake in left calcaneus 
and bilateral femur (Figure B).  From these findings, the diagnosis of multifocal 
recurrent osteomyelitis was made. No evidence of bone destruction or hyperostosis 
was observed at the time of diagnosis.  High fever continued despite the treatment with 
appropriate antibiotics and naproxen for 8 weeks.  However, she was relieved 
dramatically from high fever soon after colchicine (2mg/day) was started.  The mutation 
analysis demonstrated the heterozygous mutation of E148Q-P369S-R408Q in cis on 
one allele of MEFV gene. But no mutation wad found in LPIN2 gene. Colchicine dose 
was gradually decreased to 0.5mg/day and daily colchicine therapy (0.5mg/day) 
relieved her from febrile attacks for 1 year, although she had one episode of 
osteomyelitis in left fibula (Figure C) when the patient ceased to take colchicine.  
FMF is an autosomal recessive, inherited periodic inflammatory syndrome, 
characterized by self-limited recurrent attacks of fever with serositis such as peritonitis, 
pleuritis and arthritis [1]. The disease is common among people coming from eastern 
Mediterranean ancestry. The mainstay of treatment is cochicine which is effective for 
both relieving symptoms and preventing secondary amyloidosis. MEFV gene encodes 
a protein named pyrin, which is expressed in neutrophils and monocytes. The function 
of pyrin is still unknown and remains to be determined.  
MEFV gene had been considered to be responsible only for FMF in the past. However, 
about one-third of patients with FMF have a single mutation on one allele.  This finding 
suggests that FMF might be transferred as an autosomal dominant trait with partial 
penetration. Another possibility is that an additional, unidentified gene might be 
associated with the disease in these patients with single allele mutation.  
 Recently it has been reported a case with heterozygous MEFV mutations and distinct 
clinical presentations not typical for FMF, colchicine responsive recurrent episodes of 
muscle pains [3]. These reports including our case show MEFV gene is associated with 
more than a single disease (FMF) and is linked to additional clinical presentations 
within the family of the autoinflammatory diseases [4,5] and some rheumatic diseases 
such as s-JIA [6,7].  
 The mutation analysis in our patient demonstrated the heterozygous mutation of 
E148Q-P369S-R408Q.  In the whole list of 186 sequence alterations reported in 
Infevers - an online database for autoinflammatory mutations available at 
http://fmf.igh.cnrs.fr/ISSAID/infevers [8], this mutation is reported to be associated with 
atypical clinical presentations for FMF.   
 CRMO is an ill-defined inflammatory disease.  In typical cases, multiple bone lesions 
with apparent bone destruction, hyperostosis and pustulosis of the skin are seen [9].  
But there are variable clinical manifestations, which make differential diagnosis of 
CRMO often difficult.  LPIN2 mutation is detectable in a syndrome form of CRMO 
known as Majeed syndrome [10], but for most cases responsible gene is unknown. 
 CRMO is unusual, or unexpected manifestation for FMF, and this is the first case of 
CRMO with MEFV mutations to our knowledge. To start the treatment with colchicines 
promptly, thereby relieving symptoms and preventing secondary amyloidosis, the 
mutation analysis of MEFV gene should be performed in cases of CRMO. 
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Figure legends 
A-C: Gallium scintigraphy: the image on day3 (A) showing significant uptake in bilateral 
proximal region of tibia. day38 (B) showing significant uptake in left calcaneus and 
bilateral femur. 9 months later (C) showing significant uptake in left fibula. D: A plain X-
ray, frontal view, showed no significant findings including screlosis in bilateral tibia. E, 
F: Magnetic resonance imaging: the T1-weighted image on day3 (E) showing multiple 
lesions whose intensity was low in bilateral tibia.  The T2-weighted image on day 23 (F) 
showing multiple lesions whose intensity was high in bilateral tarsal bones  
 

